Precision Medicine Approaches For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Precision Medicine Approaches for Neurodegeneration
| Property |
Value |
| Category |
Therapeutic Strategy |
| Approach |
Genotype-guided, biomarker-stratified therapy |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, FTD |
| Goal |
Match therapies to individual patient characteristics |
| Development Stage |
Research to Early Clinical |
Precision medicine aims to tailor therapeutic interventions based on individual patient characteristics, including genetic background, biomarker profiles, disease subtype, and clinical presentation. In neurodegeneration, this approach seeks to overcome the high failure rate of clinical trials by stratifying patients and matching them to targeted therapies.
| Genetic Risk |
Therapy Approach |
Status |
| APOE ε4 carriers |
Anti-amyloid, anti-tau immunotherapy |
In trials |
| APP/PSEN1/PSEN2 mutations |
Disease-modifying therapies |
Research |
| TREM2 variants |
TREM2 agonists, microglia modulators |
Preclinical |
| Risk genes (CLU, PICALM) |
Targeted approaches |
Research |
| Genetic Risk |
Therapy Approach |
Status |
| LRRK2 G2019S |
LRRK2 inhibitors |
Phase II/III |
| GBA1 mutations |
Enzyme enhancement, chaperones |
Phase II |
| SNCA multiplications |
Anti-α-synuclein therapies |
Research |
| PARKIN, PINK1, DJ-1 |
Mitochondrial protectors |
Research |
| LRRK2 + GBA1 |
Combination approaches |
Research |
| Genetic Risk |
Therapy Approach |
Status |
| SOD1 mutations |
ASO therapy (tofersen) |
Approved |
| C9orf72 |
ASO therapy |
Phase I/II |
| FUS mutations |
ASO therapy |
Phase I |
| TARDBP |
Targeting TDP-43 |
Research |
| ALS2 |
Gene therapy |
Research |
| Genetic Feature |
Therapy Approach |
Status |
| HTT CAG repeat |
ASO therapy (tominersen) |
Phase III (failed) |
| CAG length |
Treatment timing |
Research |
| Genetic modifiers |
Personalized approaches |
Research |
| Biomarker Category |
Markers |
Clinical Use |
| A (Amyloid) |
CSF Aβ42, PET |
Patient selection |
| T (Tau) |
CSF p-tau, PET |
Staging, target engagement |
| N (Neurodegeneration) |
FDG-PET, NfL, MRI |
Disease progression |
- Diagnostic confirmation: Verify disease subtype
- Stage determination: Early vs. advanced disease
- Comorbidity screening: Mixed pathology identification
- Treatment selection: Match to biomarker profile
| Subtype |
Characteristics |
Targeted Approach |
| Typical AD |
Amnestic, amyloid+/tau+ |
Anti-amyloid/tau |
| Posterior cortical atrophy |
Visual, occipital |
Visual therapies |
| Logopenic PPA |
Language, left temporal |
Language-focused |
| Dysexecutive AD |
Frontal |
Executive function |
| Rapid progression |
Fast decline |
Aggressive therapy |
| Subtype |
Characteristics |
Targeted Approach |
| TD (Tremor-dominant) |
Tremor, slow progression |
Dopamine-sparing |
| PIGD (Postural instability) |
Falls, rapid progression |
Balance therapy |
| Cognitive |
Early dementia |
Dementia prevention |
| Mood/anxiety |
Depression, anxiety |
Mood-targeted |
| Gene |
Drug |
Effect |
Clinical Use |
| CYP2D6 |
Bromocriptine, pergolide |
Metabolism variation |
Dosing |
| COMT |
Levodopa |
Motor response |
Prediction |
| APOE |
Donepezil, immunotherapy |
Response variation |
Research |
| SCN1A |
Carbamazepine (seizures) |
Risk prediction |
Contraindication |
- Polygenic risk scores for treatment response
- Pharmacokinetic gene panels
- Adverse reaction prediction
| Design |
Description |
Advantages |
| Basket trials |
Single therapy, multiple genotypes |
Efficiency |
| Umbrella trials |
Multiple therapies, single disease |
Patient selection |
| N-of-1 trials |
Individual patient optimization |
Personalization |
| Adaptive trials |
Interim analysis, modification |
Flexibility |
- DIAN-TU: Dominantly Inherited Alzheimer's Network Trials
- Parkinson's Progression Markers Initiative (PPMI)
- ALS Genetics
- Rare Diseases
- Comprehensive genetic testing availability
- Biomarker standardization
- Data integration
- Regulatory approval for companion diagnostics
- Cost of genetic testing
- Patient access
- Physician education
- Healthcare system integration
- Genetic privacy
- Informed consent
- Incidental findings
- Health disparities
| Disease |
Therapy |
Target |
Companion Diagnostic |
| ALS (SOD1) |
Tofersen (Qalsody) |
SOD1 |
Genetic testing |
| SMA |
Nusinersen (Spinraza) |
SMN2 |
Genetic testing |
| Prion disease |
Prion disease |
PRNP |
— |
- LRRK2 inhibitors for PD (DNL151, BIIB122)
- Anti-amyloid antibodies for APOE ε4 carriers
- ASOs for C9orf72 ALS/FTD
- TREM2 agonists for AD
- Multi-omics integration
- Digital biomarker development
- Real-world evidence generation
- International data sharing
The study of Precision Medicine Approaches For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Grill JD, et al. Precision medicine in Alzheimer's disease. Journal of Alzheimer's Disease. 2020. PMID:32039456
- Schork NJ, et al. Precision medicine for Alzheimer's disease. Nature Reviews Neurology. 2019. PMID:31239547
- Pagan F, et al. Precision medicine in Parkinson's disease. Movement Disorders. 2020. PMID:32572929
- Benatar M, et al. ALS precision medicine. Neurology. 2020. PMID:32047052
- Day J, et al. Genetic stratification in Huntington's disease. Brain. 2021. PMID:33848542
- Miller T, et al. Trial of antisense oligonucleotides for SOD1-ALS. New England Journal of Medicine. 2020. PMID:32130816
- Torkamani A, et al. Genomics and precision medicine. Cell. 2018. PMID:29307484
- Frisanch O, et al. ATN framework for Alzheimer's disease. Lancet Neurology. 2018. PMID:29726460